HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zhang, P.-f. Articles by Marcus-Sekura, C. J. Search for Related Content PubMed PubMed Citation Articles by Zhang, P.-f. Articles by Marcus-Sekura, C. J. Agricola Articles by Zhang, P.-f. Articles by Marcus-Sekura, C. J.

Conformation-dependent recognition of baculovirus-expressed Epstein—Barr virus gp350 by a panel of monoclonal antibodies

Division of Viral Products, Center for Biologics Evaluation and Research, 8800 Rockville Pike, 29A, 3B-05 (HFM457), Food and Drug Administration, Rockville, Maryland 20892, U.S.A.

The Epstein—Barr virus (EBV) major membrane protein, gp350, induces antibodies that neutralize virus infectivity in vitro and is a potential candidate for an EBV vaccine. Full-length EBV gp350 and five protein fragments, encompassing the entire protein sequence, were generated in a baculovirus expression system. The recombinant proteins were analysed using a panel of 14 monoclonal antibodies (MAbs) (13 prepared against native gp350 derived from virus-producing cells and one prepared against an Escherichia coli recombinant protein). All 14 MAbs, including a virus-neutralizing antibody, reacted with the full-length recombinant gp350 in a dot blot immunoassay, but only four of the 14 MAbs reacted with polypeptides expressed by the five sub-clones, indicating that the full-length protein, but not the protein fragments, was antigenically similar to native gp350. Treatment of the six recombinant proteins with peptide-N-glycosidase F (PNGase F) indicated that the full-length gp350 protein and the N-terminal fragment were glycosylated and that the four internally initiated polypeptides were not glycosylated. PNGase F treatment of the full-length glycosylated gp350 did not eliminate its reactivity with all of the 10 MAbs examined (including the neutralizing MAb) in a dot blot immunoassay; however, denatured glycosylated gp350 lost reactivity with all but four of the 14 MAbs when analysed by either dot blot or Western blot immunoassay. The data suggest that conformational epitopes are more important in recognition of gp350 by this panel of MAbs than glycosylation sites, and that the epitope on gp350 recognized by the neutralizing MAb is conformation-and not glycosylation-dependent.

Received 26 March 1993; accepted 2 June 1993.

This article has been cited by other articles:

				M. Urquiza, R. Lopez, H. Patino, J. E. Rosas, and M. E. Patarroyo Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells J. Biol. Chem., October 21, 2005; 280(42): 35598 - 35605. [Abstract] [Full Text] [PDF]